Vor Bio (VOR) announced that the primary endpoint was achieved in Stage A of a Phase 3 clinical study in China evaluating telitacicept in adults with IgA nephropathy, IgAN. In addition, statistically significant benefits were achieved across all secondary endpoints in the study, which was conducted by RemeGen, Vor Bio’s collaborator. Telitacicept demonstrated a 55% reduction in 24-hour urine protein-to-creatinine ratio at 39 weeks compared with placebo; statistically significant benefits also achieved across all key secondary endpoints
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VOR:
- Vor Biopharma Appoints New Chief Medical Officer
- Vor Bio appoints Sokolove as Chief Medical Officer
- Vor Bio says telitacicept shows sustained efficacy in China Phase 3 study
- Vor Bio price target adjusted to $55 at H.C. Wainwright after reverse split
- Vor Biopharma Unveils Promising Phase 3 Trial Results